Acumen Pharmaceuticals, Inc.ABOSNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank59
5Y CAGR-21.5%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-21.5%/yr
Long-term compound
Percentile
P59
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 4.22% |
| Q2 2025 | 6.71% |
| Q1 2025 | -25.38% |
| Q4 2024 | -10.65% |
| Q3 2024 | -48.66% |
| Q2 2024 | 7.36% |
| Q1 2024 | -114.81% |
| Q4 2023 | 35.58% |
| Q3 2023 | -10.58% |
| Q2 2023 | -14.69% |
| Q1 2023 | 9.18% |
| Q4 2022 | -22.00% |
| Q3 2022 | -41.98% |
| Q2 2022 | 22.06% |
| Q1 2022 | -128.06% |
| Q4 2021 | 52.67% |
| Q3 2021 | -80.30% |
| Q2 2021 | -79.92% |
| Q1 2021 | 17.05% |
| Q4 2020 | -122.68% |
| Q3 2020 | 14.12% |
| Q2 2020 | 17.73% |
| Q1 2020 | 0.00% |